Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

scientific article published on 27 May 2013

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1093/EURHEARTJ/EHT187
P932PMC publication ID3743070
P698PubMed publication ID23713082
P5875ResearchGate publication ID236949397

P50authorFaiez ZannadQ19631268
Piotr PonikowskiQ22114836
Lars KøberQ33310611
Mihai GheorghiadeQ60059386
Bertram PittQ63107334
Gerasimos FilippatosQ63107352
Henry KrumQ82083581
Peter KolkhofQ99567543
Christina NowackQ114291637
P2093author name stringSo-Young Kim
P2860cites work???Q28267062
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study InvestigatorsQ28372091
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarctionQ34187441
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trialQ34751971
Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: how much is too much?Q37503827
Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeuticsQ37902778
Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseasesQ42716993
Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF).Q43101047
Eplerenone in patients with systolic heart failure and mild symptomsQ44272913
Efficacy of low-dose spironolactone in subjects with resistant hypertensionQ44628337
Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney diseaseQ57911462
Multiple neurohumoral modulating agents in systolic dysfunction heart failure: are we lowering blood pressure too much?Q81818284
2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines DeveQ83631957
P433issue31
P921main subjectpatientQ181600
heart failureQ181754
chronic renal insufficiencyQ736715
chronic heart failureQ11829287
P304page(s)2453-2463
P577publication date2013-05-27
P1433published inEuropean Heart JournalQ2286839
P1476titleSafety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
P478volume34

Reverse relations

cites work (P2860)
Q3384643130 Years of the Mineralocorticoid Receptor: Mineralocorticoid receptor antagonists: 60 years of research and development
Q41367679A Novel Aldosterone Antagonist Limits Renal Injury in 5/6 Nephrectomy
Q37098407A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
Q37720499Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy
Q38208961Aldosterone excess and resistant hypertension: investigation and treatment
Q37594892Aldosterone synthase inhibitors in hypertension: current status and future possibilities
Q38590227An update of the blockade of the renin angiotensin aldosterone system in clinical practice
Q28544460Beneficial effects of proanthocyanidins in the cardiac alterations induced by aldosterone in rat heart through mineralocorticoid receptor blockade
Q38770500Benefit of Mineralocorticoid Receptor Antagonism in AKI: Role of Vascular Smooth Muscle Rac1.
Q89752475Cardiac phenotype in propionic acidemia - Results of an observational monocentric study
Q52690991Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator.
Q26795398Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function
Q58433377Corticosteroid Receptors
Q38737757Current and emerging pharmacologic options for the management of patients with chronic and acute decompensated heart failure
Q86454230Diabetic nephropathy: Nonsteroidal MRA added to RAS blockade reduces albuminuria
Q58712499Diabetic nephropathy: newer therapeutic perspectives
Q38307958Diuretic response in acute heart failure-pathophysiology, evaluation, and therapy
Q38181208Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents
Q91142607Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice
Q57260308Effect of extended follow-up in a specialized heart failure clinic on adherence to guideline recommended therapy: NorthStar Adherence Study
Q38837657Effects of mineralocorticoid receptor antagonists on left ventricular mass in chronic kidney disease patients: a systematic review and meta-analysis
Q90765706Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats
Q26773030Efficacy and safety of mineralocorticoid receptor antagonists for patients with heart failure and diabetes mellitus: a systematic review and meta-analysis
Q38123754Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms
Q38533385Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease
Q57816948Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress
Q38850114Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.
Q38817871Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD?
Q38780801From Bench to Bedside: New Approaches to Therapeutic Discovery for Heart Failure
Q38679303Future drug discovery in renin-angiotensin-aldosterone system intervention
Q51273122Genomic and rapid effects of aldosterone: what we know and do not know thus far.
Q38800239Global cardiovascular protection in chronic kidney disease
Q90632374Glucose and Blood Pressure-Dependent Pathways-The Progression of Diabetic Kidney Disease
Q38182010Heart failure highlights in 2012-2013.
Q34019947Interfering with mineralocorticoid receptor activation: the past, present, and future
Q51741442Is there a blood pressure lowering effect of MRAs in heart failure? An overview and meta-analysis.
Q27027792Is there a new dawn for selective mineralocorticoid receptor antagonism?
Q60153626Le renouveau attendu des antagonistes du récepteur de l’aldostérone
Q61455542Long-term blockade of the renin–angiotensin system: an adequate evaluation is still needed
Q38249892Management of hyperkalaemia in chronic kidney disease
Q90470119Microalbuminuria and cardiorenal risk: old and new evidence in different populations
Q43063544Mineralocorticoid Receptor Antagonism in AKI: A New Hope?
Q89958005Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists
Q99567544Mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy
Q89454326Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice
Q34162275Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial)
Q36208986Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis
Q26741152Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives
Q58795392Mineralocorticoid receptor blockade for renoprotection
Q38161538Mineralocorticoid receptor modulators: a patent review (2007 - 2012).
Q90626583Mitigating risk of aldosterone in diabetic kidney disease
Q88711774Neurohormonal Blockade in Heart Failure
Q38845433New Agents in Treatment of Hyperkalemia: an Opportunity to Optimize Use of RAAS Inhibitors for Blood Pressure Control and Organ Protection in Patients with Chronic Kidney Disease
Q90046724New Molecules for Treating Resistant Hypertension: a Clinical Perspective
Q38429870New developments in the pharmacological treatment of hypertension: dead-end or a glimmer at the horizon?
Q34384580New drug therapies interfering with the renin-angiotensin-aldosterone system for resistant hypertension
Q38594785New medical therapies for heart failure
Q38759494New pharmacological approaches in heart failure therapy: developments and possibilities.
Q38225739Newest additions to heart failure treatment
Q38658657Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease.
Q38349798Novel RAAS agonists and antagonists: clinical applications and controversies.
Q38209074Novel drug mechanisms in development for heart failure
Q38746316Novel insights into the pathophysiology and clinical aspects of diabetic nephropathy.
Q38192513Novel molecular angiotensin converting enzyme and angiotensin receptor imaging techniques
Q50998627Outpatient management of chronic heart failure.
Q53059504Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals With Renal Impairment.
Q88738876Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug-Drug Interaction Studies In Vitro and In Vivo
Q51293660Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies.
Q47907201Pharmacologic Management for Heart Failure and Emerging Therapies
Q89903377Pharmacological interventions for heart failure in people with chronic kidney disease
Q90473703Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease
Q64100092Potassium binders for the prevention of hyperkalaemia in heart failure patients: implementation issues and future developments
Q30251531Potential new drug treatments for congestive heart failure
Q38384423Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2).
Q52688314Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion.
Q30248429Primary Aldosteronism: Changing Definitions and New Concepts of Physiology and Pathophysiology Both Inside and Outside the Kidney
Q38287146Primary aldosteronism and salt
Q90666788Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction
Q34462504Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney diseas
Q89958002Recent Research Advances in Renin-Angiotensin-Aldosterone System Receptors
Q26745900Recent advances in managing and understanding diabetic nephropathy
Q38597498Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism
Q38750210Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease
Q26746907Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies
Q101578601Role of mineralocorticoid receptor antagonists in kidney diseases
Q38746216Safety and cardiovascular effects of mineralocorticoid receptor antagonists for patients receiving hemodialysis: a systematic review and meta-analysis
Q38546917Small molecule and peptide therapies for chronic heart failure: a patent review (2011 - 2014).
Q38593070Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?
Q39199991Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside
Q36514942Sulfenic Acid Modification of Endothelin B Receptor is Responsible for the Benefit of a Nonsteroidal Mineralocorticoid Receptor Antagonist in Renal Ischemia.
Q60153622The Renin-Angiotensin-Aldosterone System in Cardiovascular Diseases
Q38168046The effect of RAAS blockade on the progression of diabetic nephropathy
Q88551678The emerging role of aldosterone/mineralocorticoid receptors in the pathogenesis of erectile dysfunction
Q41677231The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury.
Q27013946The role of the renin-angiotensin-aldosterone system in the pathobiology of pulmonary arterial hypertension (2013 Grover Conference series)
Q38766590The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure
Q52580660The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: A systematic review and meta-analysis.
Q26996385Therapeutic targeting of aldosterone: a novel approach to the treatment of glomerular disease
Q36437145Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?
Q38705827Treatment of Hyperkalemia in Heart Failure
Q33907249Treatment of diabetic kidney disease: current and future targets
Q47252893Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease

Search more.